vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and VICOR CORP (VICR). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $57.3M, roughly 2.0× RHYTHM PHARMACEUTICALS, INC.). VICOR CORP runs the higher net margin — 18.3% vs -83.0%, a 101.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 20.2%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 14.7%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
RYTM vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $113.0M |
| Net Profit | $-47.5M | $20.7M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | 59.7% |
| Net Margin | -83.0% | 18.3% |
| Revenue YoY | 36.9% | 20.2% |
| Net Profit YoY | -9.6% | 713.9% |
| EPS (diluted) | $-0.73 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $57.3M | $107.3M | ||
| Q3 25 | $51.3M | $110.4M | ||
| Q2 25 | $48.5M | $96.0M | ||
| Q1 25 | $32.7M | $94.0M | ||
| Q4 24 | $41.8M | $96.2M | ||
| Q3 24 | $33.3M | $93.2M | ||
| Q2 24 | $29.1M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $-47.5M | $46.5M | ||
| Q3 25 | $-52.9M | $28.3M | ||
| Q2 25 | $-46.6M | $41.2M | ||
| Q1 25 | $-49.5M | $2.5M | ||
| Q4 24 | $-43.3M | $10.2M | ||
| Q3 24 | $-43.6M | $11.6M | ||
| Q2 24 | $-32.3M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 91.6% | 55.4% | ||
| Q3 25 | 89.3% | 57.5% | ||
| Q2 25 | 88.6% | 95.9% | ||
| Q1 25 | 88.8% | 47.2% | ||
| Q4 24 | 90.9% | 52.4% | ||
| Q3 24 | 88.5% | 49.1% | ||
| Q2 24 | 89.9% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | -82.2% | 14.6% | ||
| Q3 25 | -102.6% | 18.9% | ||
| Q2 25 | -93.4% | 47.3% | ||
| Q1 25 | -143.7% | -0.2% | ||
| Q4 24 | -98.6% | 9.6% | ||
| Q3 24 | -132.0% | 5.8% | ||
| Q2 24 | -139.2% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | -83.0% | 43.4% | ||
| Q3 25 | -103.1% | 25.6% | ||
| Q2 25 | -96.1% | 42.9% | ||
| Q1 25 | -151.4% | 2.7% | ||
| Q4 24 | -103.6% | 10.7% | ||
| Q3 24 | -131.2% | 12.4% | ||
| Q2 24 | -110.9% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-0.73 | $1.01 | ||
| Q3 25 | $-0.82 | $0.63 | ||
| Q2 25 | $-0.75 | $0.91 | ||
| Q1 25 | $-0.81 | $0.06 | ||
| Q4 24 | $-0.71 | $0.24 | ||
| Q3 24 | $-0.73 | $0.26 | ||
| Q2 24 | $-0.55 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $754.1M |
| Total Assets | $480.2M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $388.9M | $402.8M | ||
| Q3 25 | $416.1M | $362.4M | ||
| Q2 25 | $291.0M | $338.5M | ||
| Q1 25 | $314.5M | $296.1M | ||
| Q4 24 | $320.6M | $277.3M | ||
| Q3 24 | $298.4M | $267.6M | ||
| Q2 24 | $319.1M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $139.1M | $711.6M | ||
| Q3 25 | $148.8M | $630.1M | ||
| Q2 25 | $-11.9M | $608.6M | ||
| Q1 25 | $18.9M | $580.3M | ||
| Q4 24 | $21.7M | $570.1M | ||
| Q3 24 | $11.2M | $554.6M | ||
| Q2 24 | $39.3M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $480.2M | $785.8M | ||
| Q3 25 | $506.9M | $710.2M | ||
| Q2 25 | $372.7M | $693.5M | ||
| Q1 25 | $386.7M | $665.0M | ||
| Q4 24 | $392.3M | $641.1M | ||
| Q3 24 | $363.6M | $632.8M | ||
| Q2 24 | $381.8M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-25.4M | $15.7M | ||
| Q3 25 | $-26.6M | $38.5M | ||
| Q2 25 | $-23.3M | $65.2M | ||
| Q1 25 | $-40.4M | $20.1M | ||
| Q4 24 | $-18.8M | $10.1M | ||
| Q3 24 | $-25.2M | $22.6M | ||
| Q2 24 | $-29.1M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $34.5M | ||
| Q2 25 | — | $59.0M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $8.4M | ||
| Q3 24 | — | $14.1M | ||
| Q2 24 | — | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | — | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 6.5% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 9.1% | ||
| Q2 24 | — | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
